Rahul Aggarwal

10.5k total citations
237 papers, 4.0k citations indexed

About

Rahul Aggarwal is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Rahul Aggarwal has authored 237 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Pulmonary and Respiratory Medicine, 92 papers in Oncology and 88 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Rahul Aggarwal's work include Prostate Cancer Treatment and Research (120 papers), Radiopharmaceutical Chemistry and Applications (72 papers) and Cancer Immunotherapy and Biomarkers (36 papers). Rahul Aggarwal is often cited by papers focused on Prostate Cancer Treatment and Research (120 papers), Radiopharmaceutical Chemistry and Applications (72 papers) and Cancer Immunotherapy and Biomarkers (36 papers). Rahul Aggarwal collaborates with scholars based in United States, Canada and United Kingdom. Rahul Aggarwal's co-authors include Eric J. Small, Charles J. Ryan, Thomas A. Hope, Felix Y. Feng, Peter R. Carroll, Sumit Sakhuja, Arun Kumar Sangaiah, Vipul Jain, Andrew J. Armstrong and Kim N. and has published in prestigious journals such as Proceedings of the National Academy of Sciences, JAMA and Nature Communications.

In The Last Decade

Rahul Aggarwal

216 papers receiving 4.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rahul Aggarwal United States	31	2.1k	1.5k	1.1k	969	801	237	4.0k
Arun Azad Australia	38	4.6k 2.2×	2.0k 1.3×	1.4k 1.3×	1.6k 1.6×	2.1k 2.6×	261	6.1k
Niven Mehra Netherlands	31	2.6k 1.2×	2.3k 1.5×	1.5k 1.4×	775 0.8×	1.3k 1.6×	178	4.4k
Marilyn M. Bui United States	44	1.6k 0.8×	2.0k 1.3×	1.6k 1.5×	1.3k 1.3×	1.2k 1.4×	192	6.1k
Stefan M. Willems Netherlands	41	1.3k 0.6×	2.3k 1.5×	1.7k 1.6×	563 0.6×	1.4k 1.7×	222	5.6k
Dana E. Rathkopf United States	35	3.8k 1.8×	1.7k 1.1×	1.6k 1.5×	1.3k 1.3×	1.4k 1.8×	203	5.3k
Axel Semjonow Germany	35	2.6k 1.3×	797 0.5×	1.1k 1.0×	366 0.4×	746 0.9×	170	4.2k
Daniel C. Danila United States	34	4.0k 1.9×	2.5k 1.7×	1.9k 1.7×	948 1.0×	2.8k 3.6×	130	6.6k
Evan Y. Yu United States	40	3.2k 1.6×	2.4k 1.6×	1.4k 1.3×	1.0k 1.0×	1.2k 1.5×	294	5.9k
Joaquı́n Mateo United Kingdom	34	3.2k 1.5×	3.3k 2.2×	2.1k 2.0×	742 0.8×	1.8k 2.3×	148	6.1k
Minetta C. Liu United States	36	1.6k 0.8×	3.4k 2.3×	1.9k 1.7×	469 0.5×	2.9k 3.6×	204	6.0k

Countries citing papers authored by Rahul Aggarwal

Since Specialization

Citations

This map shows the geographic impact of Rahul Aggarwal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rahul Aggarwal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rahul Aggarwal more than expected).

Fields of papers citing papers by Rahul Aggarwal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rahul Aggarwal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rahul Aggarwal. The network helps show where Rahul Aggarwal may publish in the future.

Co-authorship network of co-authors of Rahul Aggarwal

This figure shows the co-authorship network connecting the top 25 collaborators of Rahul Aggarwal. A scholar is included among the top collaborators of Rahul Aggarwal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rahul Aggarwal. Rahul Aggarwal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kwon, Daniel H., Maren T. Scheuner, Evan J. Walker, et al.. (2024). Germline testing for veterans with advanced prostate cancer: concerns about service-connected benefits. JNCI Cancer Spectrum. 8(5). 1 indexed citations

Kwon, Daniel H., Hala T. Borno, Rohit Bose, et al.. (2024). Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer Medicine. 13(22). e70433–e70433.

Choudhury, Noura J., Himisha Beltran, Erin L. Schenk, et al.. (2024). OA10.06 Impact of Brain Metastases on Safety and Efficacy of MK-6070, a DLL3-Targeting T Cell Engager, in Small Cell Lung Cancer. Journal of Thoracic Oncology. 19(10). S32–S33. 4 indexed citations

Zhang, Meng, Martin Sjöström, Xiekui Cui, et al.. (2024). Integrative analysis of ultra-deep RNA-seq reveals alternative promoter usage as a mechanism of activating oncogenic programmes during prostate cancer progression. Nature Cell Biology. 26(7). 1176–1186. 2 indexed citations

Oh, David Y., Anthony Wong, Katsuto Shinohara, et al.. (2023). 862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients. SHILAP Revista de lepidopterología. A961–A961. 1 indexed citations

Rathmell, W. Kimryn, Geoffrey I. Shapiro, Jordi Rodón, et al.. (2023). A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.. Journal of Clinical Oncology. 41(16_suppl). 3104–3104. 2 indexed citations

Lim, Emerson A., Michael T. Schweizer, Kim N., et al.. (2023). Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(3). 366–375. 32 indexed citations

Tsang, Erica S., Rahul Aggarwal, Emily K. Bergsland, et al.. (2022). A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Research Communications. 2(7). 570–576. 6 indexed citations

Aggarwal, Rahul, Alexander Starodub, Brian D. Koh, et al.. (2022). Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 28(18). 3979–3989. 18 indexed citations

10.

Murthy, Vishnu, Rahul Aggarwal, & Phillip J. Koo. (2022). The Emerging Role of Next-Generation Imaging in Prostate Cancer. Current Oncology Reports. 24(1). 33–42. 6 indexed citations

11.

Han, Harry J., et al.. (2020). Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Therapeutic Advances in Medical Oncology. 12. 3863551124–3863551124. 15 indexed citations

12.

Aggarwal, Rahul, Michael T. Schweizer, David M. Nanus, et al.. (2020). A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(20). 5338–5347. 97 indexed citations

13.

Huang, Yangjie, Ning Zhao, Yung-Hua Wang, et al.. (2020). A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chemical Biology. 15(6). 1381–1391. 4 indexed citations

14.

Aggarwal, Rahul, Verena Friedl, Alana S. Weinstein, et al.. (2020). Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 24(1). 81–87. 17 indexed citations

15.

Aggarwal, Rahul, David A. Quigley, Jiaoti Huang, et al.. (2019). Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research. 17(6). 1235–1240. 40 indexed citations

16.

Bartelink, Imke H., Rahul Aggarwal, Jim Leng, et al.. (2017). Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clinical Cancer Research. 23(21). 6400–6410. 58 indexed citations

17.

Aggarwal, Rahul, Spencer C. Behr, Pamela L. Paris, et al.. (2017). Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research. 15(9). 1221–1229. 12 indexed citations

18.

Aggarwal, Rahul, Scott Thomas, Nela Pawłowska, et al.. (2017). Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies. Journal of Clinical Oncology. 35(11). 1231–1239. 76 indexed citations

19.

Joseph, Gabby B., Adam Foye, Daria Motamedi, et al.. (2017). CT–Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. Journal of Vascular and Interventional Radiology. 28(8). 1073–1081.e1. 24 indexed citations

20.

Münster, Pamela N., Rahul Aggarwal, David S. Hong, et al.. (2015). First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clinical Cancer Research. 22(8). 1932–1939. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact